目的:探讨叉头盒蛋白M1 (FOXM1)和Polo样激酶(PLK1)在子宫内膜癌中的表达,并分析两者表达的相关性及其临床意义。方法:以免疫组织化学染色的方法检测FOXM1和PLK1分别在子宫内膜癌、不典型增生和正常子宫内膜组织中的表达水平,然后分析...目的:探讨叉头盒蛋白M1 (FOXM1)和Polo样激酶(PLK1)在子宫内膜癌中的表达,并分析两者表达的相关性及其临床意义。方法:以免疫组织化学染色的方法检测FOXM1和PLK1分别在子宫内膜癌、不典型增生和正常子宫内膜组织中的表达水平,然后分析两者在子宫内膜癌中表达水平的相关性,以及两者分别与临床病理参数之间的关系。结果:1) FOXM1和PLK1在子宫内膜癌组织中的表达水平明显高于正常子宫内膜组织和不典型增生内膜组织(P r = 0.310, P = 0.030)。结论:FOXM1和PLK1可能在子宫内膜癌的进展过程中发挥重要作用,二者的相互作用具有成为子宫内膜癌诊断生物标志物的潜能。Objective: This study aimed to investigate the expression levels of forkhead box M1 (FOXM1) and polo-like kinase 1 (PLK1) in endometrial carcinoma, analyze their correlation, and evaluate their clinical significance. Methods: Immunohistochemistry was employed to detect the expression of FOXM1 and PLK1 in endometrial carcinoma tissues, atypical hyperplasia endometrial tissues, and normal endometrial tissues. The correlation between FOXM1 and PLK1 expression in endometrial carcinoma and their associations with clinicopathological parameters were further analyzed. Results: 1) The expression levels of FOXM1 and PLK1 were significantly elevated in endometrial carcinoma compared to atypical hyperplasia and normal endometrial tissues (P < 0.05). 2) High expression of FOXM1 was associated with FIGO stage and lymph node metastasis in endometrial carcinoma (P < 0.05), while high expression of PLK1 was correlated with pathological grade, FIGO stage, and lymph node metastasis (P < 0.05). 3) A positive correlation was observed between FOXM1 and PLK1 expression in endometrial carcinoma tissues (r = 0.310, P = 0.030). Conclusion: FOXM1 and PLK1 may play critical roles in the progression of endometrial carcinoma. Targeting these molecules could serve as a potential diagnostic and therapeutic strategy for endometrial carcinoma.展开更多
目的基于网状meta分析口服中成药联合西药治疗冠心病合并高脂血症的有效性和安全性。方法运用计算机检索中国知网(CNKI)、万方数据(WANFANG DATA)、维普(VIP)、SinoMed、PubMed、Web of Science、Cochrane Library数据库中2019年1月—2...目的基于网状meta分析口服中成药联合西药治疗冠心病合并高脂血症的有效性和安全性。方法运用计算机检索中国知网(CNKI)、万方数据(WANFANG DATA)、维普(VIP)、SinoMed、PubMed、Web of Science、Cochrane Library数据库中2019年1月—2023年12月所有的口服中成药联合西药治疗冠心病合并高脂血症的临床随机试验(randomized controlled trial,RCT),将检索到的文献进行筛选,确定最终纳入文献并提取数据,用Stata 14、Revman 5.4进行统计分析。结果纳入56篇RCTs,共5080例患者,包括16种口服中成药。根据网状meta分析显示,在临床有效率方面,累积排名曲线下面积(surface under the cumulative ranking curve,SUCRA)概率排位前3为脂必泰、延丹胶囊、通心络胶囊;在甘油三酯方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、麝香保心丸;在总胆固醇方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、脂必妥;在低密度脂蛋白胆固醇方面,SUCRA概率排序前3为冠心宁片、脂必妥、心可舒胶囊;在高密度脂蛋白胆固醇方面,SUCRA概率排序前3为麝香保心丸、脂必妥、冠心宁片;在左心室射血分数方面,SUCRA概率排序前3为通心络胶囊、复方丹参滴丸、麝香保心丸。结论口服中成药联合西药治疗冠心病合并高脂血症的疗效优于单独西药治疗。展开更多
文摘目的:探讨叉头盒蛋白M1 (FOXM1)和Polo样激酶(PLK1)在子宫内膜癌中的表达,并分析两者表达的相关性及其临床意义。方法:以免疫组织化学染色的方法检测FOXM1和PLK1分别在子宫内膜癌、不典型增生和正常子宫内膜组织中的表达水平,然后分析两者在子宫内膜癌中表达水平的相关性,以及两者分别与临床病理参数之间的关系。结果:1) FOXM1和PLK1在子宫内膜癌组织中的表达水平明显高于正常子宫内膜组织和不典型增生内膜组织(P r = 0.310, P = 0.030)。结论:FOXM1和PLK1可能在子宫内膜癌的进展过程中发挥重要作用,二者的相互作用具有成为子宫内膜癌诊断生物标志物的潜能。Objective: This study aimed to investigate the expression levels of forkhead box M1 (FOXM1) and polo-like kinase 1 (PLK1) in endometrial carcinoma, analyze their correlation, and evaluate their clinical significance. Methods: Immunohistochemistry was employed to detect the expression of FOXM1 and PLK1 in endometrial carcinoma tissues, atypical hyperplasia endometrial tissues, and normal endometrial tissues. The correlation between FOXM1 and PLK1 expression in endometrial carcinoma and their associations with clinicopathological parameters were further analyzed. Results: 1) The expression levels of FOXM1 and PLK1 were significantly elevated in endometrial carcinoma compared to atypical hyperplasia and normal endometrial tissues (P < 0.05). 2) High expression of FOXM1 was associated with FIGO stage and lymph node metastasis in endometrial carcinoma (P < 0.05), while high expression of PLK1 was correlated with pathological grade, FIGO stage, and lymph node metastasis (P < 0.05). 3) A positive correlation was observed between FOXM1 and PLK1 expression in endometrial carcinoma tissues (r = 0.310, P = 0.030). Conclusion: FOXM1 and PLK1 may play critical roles in the progression of endometrial carcinoma. Targeting these molecules could serve as a potential diagnostic and therapeutic strategy for endometrial carcinoma.
文摘目的基于网状meta分析口服中成药联合西药治疗冠心病合并高脂血症的有效性和安全性。方法运用计算机检索中国知网(CNKI)、万方数据(WANFANG DATA)、维普(VIP)、SinoMed、PubMed、Web of Science、Cochrane Library数据库中2019年1月—2023年12月所有的口服中成药联合西药治疗冠心病合并高脂血症的临床随机试验(randomized controlled trial,RCT),将检索到的文献进行筛选,确定最终纳入文献并提取数据,用Stata 14、Revman 5.4进行统计分析。结果纳入56篇RCTs,共5080例患者,包括16种口服中成药。根据网状meta分析显示,在临床有效率方面,累积排名曲线下面积(surface under the cumulative ranking curve,SUCRA)概率排位前3为脂必泰、延丹胶囊、通心络胶囊;在甘油三酯方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、麝香保心丸;在总胆固醇方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、脂必妥;在低密度脂蛋白胆固醇方面,SUCRA概率排序前3为冠心宁片、脂必妥、心可舒胶囊;在高密度脂蛋白胆固醇方面,SUCRA概率排序前3为麝香保心丸、脂必妥、冠心宁片;在左心室射血分数方面,SUCRA概率排序前3为通心络胶囊、复方丹参滴丸、麝香保心丸。结论口服中成药联合西药治疗冠心病合并高脂血症的疗效优于单独西药治疗。
